AU2021356687A1 - Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride - Google Patents

Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Download PDF

Info

Publication number
AU2021356687A1
AU2021356687A1 AU2021356687A AU2021356687A AU2021356687A1 AU 2021356687 A1 AU2021356687 A1 AU 2021356687A1 AU 2021356687 A AU2021356687 A AU 2021356687A AU 2021356687 A AU2021356687 A AU 2021356687A AU 2021356687 A1 AU2021356687 A1 AU 2021356687A1
Authority
AU
Australia
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021356687A
Other languages
English (en)
Other versions
AU2021356687A9 (en
Inventor
Michael De Vivo
Friso POSTMA
Robert RISINGER
Frank Yocca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of AU2021356687A1 publication Critical patent/AU2021356687A1/en
Publication of AU2021356687A9 publication Critical patent/AU2021356687A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021356687A 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Abandoned AU2021356687A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (2)

Publication Number Publication Date
AU2021356687A1 true AU2021356687A1 (en) 2023-06-15
AU2021356687A9 AU2021356687A9 (en) 2024-10-03

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021356687A Abandoned AU2021356687A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102793584B1 (ko) 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
CA2924190C (en) * 2013-10-07 2019-07-09 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
KR102793584B1 (ko) * 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN

Also Published As

Publication number Publication date
JP2023545372A (ja) 2023-10-30
EP4225305A4 (en) 2024-10-23
CA3195133A1 (en) 2022-04-14
WO2022076818A1 (en) 2022-04-14
MX2023003993A (es) 2023-05-24
KR20230084186A (ko) 2023-06-12
EP4225305A1 (en) 2023-08-16
CN116615243A (zh) 2023-08-18
AU2021356687A9 (en) 2024-10-03
IL301971A (en) 2023-06-01
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US11998529B2 (en) Non-sedating dexmedetomidine treatment regimens
US20240024289A1 (en) Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
TW202019388A (zh) 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
US20250319069A1 (en) Methods for treating depressive states
JP2006508122A (ja) チザニジンの頬及び舌下デリバリーのための医薬組成物及び投与形態並びにチザニジンを舌下又は頬に投与する方法
WO2024263973A1 (en) Dexmedetomidine treatment regimens
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения
EA040771B1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period